These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32829355)

  • 1. [Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].
    Funasaka C; Kanemasa Y; Kageyama A; Shimoyama T; Omuro Y
    Gan To Kagaku Ryoho; 2020 Aug; 47(8):1205-1208. PubMed ID: 32829355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
    Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
    Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
    Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
    Kobayashi N; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Hiroshima Y; Ichikawa Y
    Cancer Sci; 2021 May; 112(5):1936-1942. PubMed ID: 33453146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.
    Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ichimura T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
    Cancer Manag Res; 2019; 11():5757-5764. PubMed ID: 31417315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
    Araki T; Takashima A; Hamaguchi T; Honma Y; Iwasa S; Okita N; Kato K; Yamada Y; Hashimoto H; Taniguchi H; Kushima R; Nakao K; Boku N; Shimada Y
    Anticancer Drugs; 2016 Sep; 27(8):794-9. PubMed ID: 27341105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Analysis of Extrapulmonary Neuroendocrine Carcinoma: A Retrospective and Single Institution Experience.
    Okumura T; Noguchi T; Sekiguchi N; Kobayashi T; Kanda S; Ida K; Minagawa T; Tokumaru S; Umemura T; Koizumi T
    Chemotherapy; 2023; 68(2):87-94. PubMed ID: 36327945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
    Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
    Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.
    Ando T; Hosokawa A; Yoshita H; Ueda A; Kajiura S; Mihara H; Nanjo S; Fujinami H; Nishikawa J; Ogawa K; Nakajima T; Imura J; Sugiyama T
    Gastroenterol Res Pract; 2015; 2015():425876. PubMed ID: 26199623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
    Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
    Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
    Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
    Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
    Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
    Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
    Asayama M; Fuse N; Yoshino T; Yano T; Tahara M; Doi T; Fujii S; Ohtsu A
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1325-30. PubMed ID: 21461890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.
    de M Rêgo JF; de Medeiros RSS; Braghiroli MI; Galvão B; Neto JEB; Munhoz RR; Guerra J; Nonogaki S; Kimura L; Pfiffer TE; de Castro G; Hoff PM; Filho DR; Costa FP; Riechelmann RP
    Ecancermedicalscience; 2017; 11():767. PubMed ID: 28955403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
    Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
    Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.
    Igawa S; Yamamoto N; Ueda S; Ono A; Nakamura Y; Tsuya A; Murakami H; Endo M; Takahashi T
    J Thorac Oncol; 2007 Aug; 2(8):741-4. PubMed ID: 17762341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
    Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.